K2 Principal Fund’s PharmaCyte Biotech PMCB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-209,266
| Closed | -$400K | – | 294 |
|
|
2024
Q3 | $400K | Sell |
209,266
-118,237
| -36% | -$226K | 0.06% | 137 |
|
|
2024
Q2 | $642K | Hold |
327,503
| – | – | 0.12% | 109 |
|
|
2024
Q1 | $776K | Buy |
327,503
+22,890
| +8% | +$54.2K | 0.13% | 99 |
|
|
2023
Q4 | $655K | Buy |
304,613
+46,132
| +18% | +$99.2K | 0.08% | 92 |
|
|
2023
Q3 | $543K | Buy |
258,481
+104,249
| +68% | +$219K | 0.11% | 71 |
|
|
2023
Q2 | $441K | Sell |
154,232
-569,039
| -79% | -$1.63M | 0.1% | 84 |
|
|
2023
Q1 | $2.06M | Sell |
723,271
-8,834
| -1% | -$25.2K | 0.28% | 48 |
|
|
2022
Q4 | $2.15M | Buy |
732,105
+120,942
| +20% | +$354K | 0.33% | 42 |
|
|
2022
Q3 | $1.47M | Buy |
611,163
+520,068
| +571% | +$1.25M | 0.17% | 59 |
|
|
2022
Q2 | $204K | Buy |
+91,095
| New | +$204K | 0.02% | 139 |
|